2013 Trend: Smarter Computer Validation
Having been around when dinosaurs roamed the earth and computer validation was “invented,” I am sorry to say that things haven’t changed that much across the industry. Validation of computer systems was originally expected by regulators and subsequently introduced in the manufacturing (cGMP) and lab systems (GLP) arenas. Clinical departments were loath to adopt validation requirements and, to this day, still seem reluctant to accept these requirements.
Over the years, the “validation community” (QA, IT, business functions, etc.) has been very well intended, with many members attempting to promote the ideas that good software development life cycle (SDLC) practices—including documented testing—made good business sense and we shouldn’t look at computer validation as simply a regulatory requirement. Unfortunately, the validation community as a whole generally failed to get this message across; and to this day, many companies, including many software development organizations within those companies, see validation as a necessary evil to be avoided or minimized at all costs.
Those companies, such as Medidata, who have adopted a more enlightened approach to validation have reaped the benefits of more effective and efficient software development practices and most importantly, higher quality software solutions. In particular, great success has been seen in incorporating validation principles within the SDLC process itself, rather than treating validation as a separate exercise. In addition, more modern development and testing practices, such as those based on the agile methodology, result in higher quality solutions, while still generating the necessary documentation expected by regulators.
In 2013, I see even more companies adopting this smarter approach to computer validation and reaping the benefits of a more effective and efficient validation practice.
More on Fran Nolan
Comments in this post
Leave a reply
- Providing Clarity on the Definitions of Source Data Verification (SDV) and Source Data Review (SDR)
- The Opportunities and Challenges for the Chinese Life Sciences Industry
- Pharma R&D Veteran Annalisa Jenkins On Diversity as a Tool for Innovation
- Eisai Chief Medical Officer Stewart Geary On Clinical Trial Complexity
- “Painful Memories” – How Memory Biases Affect Patient-reported Outcome Measures
The global head of research ...Eli Lilly And Company Has A Plan To ...
Chito Zulueta was appointed pre ...Pharma R&D Veteran Annalisa Jenkins ...
We recently visited Dimensi ...Eisai Chief Medical Officer Stewart ...
Clinical trial costs are increa ...The Opportunities and Challenges fo ...
We published an article on th ...
“Painful Memories” – How Memory Biases Affect Patient-reported Outcome Measures
In a way the patients memories are accurate if you think of them remembering "average pain" rather than "peak pain"...
Taking ePRO to New Places – Replacing Paper
Clear and concise description of Patient Cloud cost benefits vs. Paper. Used it today!
What Advocates Said to Congress During Rare Disease Week on the Hill
Great post Steve. I am mother to Hunter, a RARE terminal ill three year old with SMA Type 1. I'm...
Are Your Data Cleaning Cycle Times Out of Control?
Steve, I'm confused about this graph. You say that time from visit to query close is in the 30 day...
Amgen Team Discuss Study Design, Data Monitoring and Clinical Integrations at 2012 A-MUG
Every visit we are treated by freldniy staff and doctors! They remember us personally and are very courteous with every...
Clinical Data Analytics
Clinical Study Design
Clinical Trial Budgeting
Clinical Trial Management
Clinical Trial Phases
Cloud Computing, SaaS and PaaS
ePRO and mHealth
FDA and Regulatory Affairs
Innovation and Entrepreneurship
Interoperability and eClinical
Randomization and Clinical Trial Supply
Site Engagement and Monitoring
Technology and Agile Development